PanINs. "There are currently no tests with sufficient sensitivity and specificity to detect pancreatic cancer early enough to attempt a cure, and no test of any kind exists to identify premalignant disease. Because of the super-aggressive nature of this disease, the only hope for cure comes from the ability to identify the preinvasive condition. Our research identifies a protein signature that can signal the earliest stage of this disease and may even be useful to identify therapeutic targets in pancreatic cancer," explains Dr. Tuveson.

'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2829
Cell Press
10-Dec-2003

Page: 1 2
Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View